Delisting risk
Elutia
Develops drug-eluting biomatrices for surgical reconstruction and implanted-device complications.
$0.8800
After-hours close−0.00 (−0.18%)
At close$0.8816(+0.18%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.15 | — | — |
| Aug 2026 | −$0.15 | −$0.17 | −13.3% |
| May 2026 | −$0.15 | −$0.17 | −13.3% |
| Mar 2026 | −$0.14 | −$0.14 | 0.0% |
| Nov 2025 | −$0.16 | −$0.01 | +93.5% |
The latest year is open to everyone — the 16 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.15 | — | — | $1.0M | — | — |
| Aug 13, 2026 | −$0.15 | −$0.17 | −13.3% | $2.9M | $2.4M | −16.3% |
| May 14, 2026 | −$0.15 | −$0.17 | −13.3% | $3.0M | $3.1M | +3.8% |
| Mar 11, 2026 | −$0.14 | −$0.14 | 0.0% | $3.3M | $3.3M | −0.9% |
| Nov 6, 2025 | −$0.16 | −$0.01 | +93.5% | $3.3M | $3.3M | +0.7% |
The latest year is open to everyone — the 16 quarters behind it read with an account. Sign in | ||||||
| Aug 14, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 6, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 7, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 7, 2024 | ||||||
| Nov 13, 2023 | ||||||
| Aug 14, 2023 | ||||||
| May 10, 2023 | ||||||
| Mar 22, 2023 | ||||||
| Sep 29, 2022 | ||||||
| Jun 29, 2022 | ||||||
| Mar 30, 2022 | ||||||
| Dec 30, 2021 | ||||||
| Sep 29, 2021 | ||||||